Commercialization of Cyclodextrin Products Through New Applications and Combinations With New Materials
First written in FY2018. 7 of 12 entries say "Restated". Latest entry: FY2023.
The whole theme swung hardest in 2024: 2 of 8 companies on the "Worse" side.
4 other companies' latest entry also says "Restated".
- FY2023RestatedAnnual report
「The cyclodextrin segment will pursue further technological improvements and other initiatives to advance the business.」
The company continues its policy of technological improvements in the cyclodextrin business. - FY2022RestatedAnnual report
「Sales of contract-processed products remained sluggish, resulting in revenue below the same period of the previous year.」
The company continues its cyclodextrin business, including sales of contract-manufactured products, but full-year net sales fell below the previous year. - FY2021Focus on technological improvementsAnnual report
「The cyclodextrin segment will pursue further technological improvements and other initiatives to advance the business.」
In addition to its policy of developing new applications and commercializing products, the company explicitly identified further technological improvements as a means of advancing the business. - FY2020AdvancedAnnual report
「The cyclodextrin segment will pursue the development of new applications and commercialization through combinations with new materials, while strengthening its sales capabilities and expanding sales.」
The company continued its full-year business strategy of developing new applications, commercializing products through combinations with new materials, and strengthening its sales capabilities, while sales of key items and secondary-processed products remained firm. - FY2020-Q3AdvancedAnnual report
「Sales to major users of key products and processed products remained strong, resulting in higher revenue and profit for the cyclodextrin segment as a whole.」
Sales to major users, including secondary-processed products, remained strong, resulting in higher revenue and higher profit for the cyclodextrin segment as a whole. - FY2020-Q2ReframedAnnual report
「The cyclodextrin segment actively expanded sales of processed products using cyclodextrin and manufactured products on a contract-processing basis at customers' request. As a result, the segment as a whole recorded lower revenue but higher profit.」
The wording of the measures explicitly stated in this filing has changed from commercialization through combinations of new applications and new materials to expanding sales of secondary-processed products and contract manufacturing and processing at users' request. - FY2020-Q1RestatedAnnual report
「The cyclodextrin segment worked to expand sales through the development of new applications and stronger sales capabilities for food and non-food products. As a result, sales volume was below the previous year, while revenue exceeded the previous year.」
The company continues to expand sales through the development of new applications for food and non-food products and stronger sales capabilities. - FY2019RestatedAnnual report
「We will pursue commercialization through the development of new applications and combinations with new materials, while strengthening our sales capabilities and expanding sales.」
The company continues to pursue a policy of expanding sales through commercialization based on combinations of new applications and new materials and stronger sales capabilities. - FY2019-Q3RestatedAnnual report
「The cyclodextrin segment worked to expand sales through the development of new applications and materials and stronger sales capabilities for food and non-food products, but revenue was below the previous year.」
The company continues to expand sales through the development of new applications and materials for food and non-food products and stronger sales capabilities. - FY2019-Q2RestatedAnnual report
「The cyclodextrin segment worked to expand sales through the development of new applications and materials and stronger sales capabilities for food and non-food products, but revenue was below the previous year.」
The company continues to expand sales of cyclodextrin through the development of new applications and materials and stronger sales capabilities. - FY2019-Q1RestatedAnnual report
「The cyclodextrin segment worked to expand sales through the development of new applications and stronger sales capabilities for food and non-food products. As a result, sales volume was below the previous year, while revenue exceeded the previous year.」
The company is reiterating its plan to expand sales of cyclodextrin through the development of new applications and stronger sales capabilities. - FY2018First statedAnnual report
「We will pursue commercialization through the development of new applications and combinations with new materials, while strengthening our sales capabilities and expanding sales.」
In addition to expanding sales to existing food and non-food markets, this indicates new applications, combinations with new materials, commercialization and stronger sales capabilities.